Everything below concerns synthetic peptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-09-07. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
== People == C. Rajagopalachari, Indian politician Christina Ricci, American actress Chris Rock, American comedian and actor Cristiano Ronaldo, Portuguese footballer Christopher Reeve, American actor A Royal cypher representing a monarch Charles Rex (CR / CIIIR), the royal cypher of King Charles III
Despite Hezbollah claiming no attacks against Israel, Israel continued airstrikes across southern Lebanon, the southern suburbs of Beirut and the eastern Beqaa Valley in what was dubbed "Operation Eternal Darkness". In the span of just 10 minutes, 100 airstrikes were launched in Lebanon by Israel during the operation (10 every minute), targeting Hezbollah assets including headquarters, intelligence centers, missile infrastructure, sites related to the Radwan Force and aerial and naval units. Israel stated they had managed to kill Ali Yusuf Harshi, the secretary of Hezbollah's leader at the time. After that, Israel continued fighting. At Iran, authorities claimed for some Israeli violations on their country according to reports. Reports of strikes nearby Tehran and Isfahan were reported. An Israeli drone was allegedly shot down in the vicinity of the city of Lar.
About 98.5% of the oxygen in a sample of arterial blood in a healthy human breathing air at sea-level pressure is chemically combined with the hemoglobin. About 1.5% is physically dissolved in the other blood liquids and not connected to hemoglobin. The hemoglobin molecule is the primary transporter of oxygen in mammals and many other species. Hemoglobin has an oxygen binding capacity between 1.36 and 1.40 ml O2 per gram hemoglobin, which increases the total blood oxygen capacity seventyfold, compared to if oxygen solely were carried by its solubility of 0.03 ml O2 per liter blood per mm Hg partial pressure of oxygen (about 100 mm Hg in arteries). With the exception of pulmonary and umbilical arteries and their corresponding veins, arteries carry oxygenated blood away from the heart and deliver it to the body via arterioles and capillaries, where the oxygen is consumed; afterwards, venules and veins carry deoxygenated blood back to the heart. Under normal conditions in adult humans at rest, hemoglobin in blood leaving the lungs is about 98–99% saturated with oxygen, achieving an oxygen delivery between 950 and 1150 ml/min to the body. In a healthy adult at rest, oxygen consumption is approximately 200–250 ml/min, and deoxygenated blood returning to the lungs is still roughly 75% (70 to 78%) saturated.
==== Vietnam and wide tobacco-related costs ==== In Vietnam, the e-cigarette market is growing rapidly, with the use rate increasing 18 times from 2015 to 2020. The use rate of e-cigarettes in adolescents aged 13–15 is 3.5%, up 1.6% from 2019. According to estimates by the World Health Organization (WHO), the global economic losses caused by tobacco each year are $1.4 trillion. Economic losses caused by tobacco are estimated to account for 1% of GDP. The Vietnamese government is making efforts to control the e-cigarette market. However, here are still many challenges to be addressed, such as consumer's lack of understanding of the harm of e-cigarettes, unclear legal regulations, and fierce competition from imported e-cigarette products.
Sources: en.wikipedia.org
Psychemedics hair tests are available in Brazil through the company's independent distributor, Psychemedics Brazil. The partnership goes back over 15 years and the drug tests are provided at clinics throughout Brazil, and then shipped to the lab in Culver City, California for analysis. Hair testing analyzes the hair shaft, rather than body fluids like urine or saliva, to determine whether illegal drugs are present. Compared to analysis of body fluids, hair testing is highly resistant to evasion by adulterating or substituting samples, or by simply abstaining from drug use for a few days. Though Psychemedics previously used a proprietary radio immunoassay (RIA) method, they have since switched to the industry-standard enzyme immunoassay screening method, which has been successfully employed for years by competitors such as Quest Diagnostics. They use GC/MS/MS or LC/MS/MS confirmation to measure the drug molecules and metabolites within the hair which were incorporated following ingestion. The Psychemedics technology includes tests for cocaine, marijuana, opiates (including heroin and oxycodone), methamphetamine, Ecstasy (MDMA), Eve (MDEA) and phencyclidine (PCP). A standard test of approximately one-and-one-half inches of head hair cut close to the scalp can provide a several month window to detect drug ingestion. In 2013, Psychemedics Corporation began offering hair based alcohol Ethyl glucuronide testing. This testing was previously attempted by laboratories in the United Kingdom, but has suffered from numerous lawsuits.
=== Nausea and vomiting === Tolerance to nausea occurs within 7–10 days, during which antiemetics (e.g. low dose haloperidol once at night) are very effective. Due to severe side effects such as tardive dyskinesia, haloperidol is now rarely used. A related drug, prochlorperazine is more often used, although it has similar risks. Stronger antiemetics such as ondansetron or tropisetron are sometimes used when nausea is severe or continuous and disturbing, despite their greater cost. A less expensive alternative is dopamine antagonists such as domperidone and metoclopramide. Domperidone does not cross the blood–brain barrier and produce adverse central antidopaminergic effects, but blocks opioid emetic action in the chemoreceptor trigger zone. This drug is not available in the U.S. Some antihistamines with anticholinergic properties (e.g. orphenadrine, diphenhydramine) may also be effective. The first-generation antihistamine hydroxyzine is commonly used, with the added advantages of not causing movement disorders, and also possessing analgesic-sparing properties. THC relieves nausea and vomiting; it also produces analgesia that may allow lower doses of opioids with reduced nausea and vomiting.
CEEs are a combination of estrogens, or agonists of the estrogen receptors. The major estrogen in CEEs, sodium estrone sulfate, itself is inactive, and rather serves as a prodrug of estrone and then of estradiol. The transformation of estrone sulfate to estrone is catalyzed by steroid sulfatase, and of estrone into estradiol by 17β-hydroxysteroid dehydrogenase. CEEs (as Premarin) and estrone have been found to be equivalent in potency in an animal model of estrogenic activity. On the other hand, the active forms of the equine estrogens in CEEs, such as equilin and 17β-dihydroequilin, have greater potency in the liver relative to bioidentical estradiol, similarly to synthetic estrogens like ethinylestradiol and diethylstilbestrol. This results in disproportionate effects on liver protein production compared to estradiol, although to a lesser extent than ethinylestradiol and diethylstilbestrol. In addition, 17β-dihydroequilenin has shown a selective estrogen receptor modulator (SERM)-like profile of estrogenic activity in studies with monkeys, in which beneficial effects on bone and the cardiovascular system were observed but proliferative responses in breast or endometrium were not seen, although the clinical significance of this is unknown. CEEs consists of the sodium salts of the sulfate esters of equine estrogens in a specific and consistent composition (see the table). The major estrogens in CEEs are sodium estrone sulfate and sodium equilin sulfate, which together account for approximately 71.5–92.0% of the total content of CEEs.
Sources: en.wikipedia.org
Digital forensics, one application of which is to recover hidden or deleted data. Ballistics analysis which involves the evaluation of ammunition and firearms to determine which weapon might have been used in a crime. Forensic anthropology which analyzes skeletal remains to determine their cause of death or any other relevant information. Mobile forensics and social media which, since their creation, have had increased involvement in any police case, cold or not. Forensic psychology which can be used to analyze crime scenes and identify suspect profiles. Facial recognition which has been used to identify suspects based on their facial features. Artificial intelligence (AI) which is used in all of the above systems to help analyze data and information from crime scenes.
=== Safety for humans === One of the great advantages of the Sendai virus as a potential oncolytic agent is its safety. Even though the virus is widespread in rodent colonies and has been used in laboratory research for decades, it has never been observed that it can cause human disease. Moreover, Sendai virus has been used in clinical trials involving both adults and 1–6-year-old children. to immunize against human parainfluenza virus type 1, since the two viruses share common antigenic determinants and trigger the generation of cross-reactive neutralizing antibodies. The Sendai virus administration in the form of nasal drops in doses ranging from 5 × 105 50% embryo infectious dose (EID50) to 5 × 107 EID50 induced the production of neutralizing antibodies to the human virus without any measurable side effects. The results of these trials represent additional evidence of Sendai virus safety for humans. The development of T cell-based AIDS vaccines using Sendai virus vectors reached phase II clinical trial. Evaluation of the safety and immunogenicity of an intranasally administered replication-competent Sendai virus–vectored HIV Type 1 gag vaccine demonstrated: induction of potent T-cell and antibody responses in prime-boost regimens. Sendai virus also used as a backbone for vaccine against respiratory syncytial virus (RSV).
== External links == Tree Family Betulaceae Diagnostic photos of many species, Morton Arboretum specimens Eichhorn, Markus (July 2010). "The Birch Tree". Test Tube. Brady Haran for the University of Nottingham.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.